Armata says FDA grants Breakthrough Therapy designation for AP-SA02 in complicated Staph aureus bacteremia

• Armata Pharmaceuticals received FDA Breakthrough Therapy designation for AP-SA02 in adjunct treatment of complicated Staphylococcus aureus bacteremia.
• Designation was supported by results already presented from a Phase 1b/2a study in adults with complicated bloodstream infection.
• AP-SA02 showed better overall patient outcomes than placebo when added to best-available antibiotics, with fewer relapses during follow-up.
• Regulatory status strengthens the program’s development outlook, with Fast Track and QIDP designations already in place.
• Company positioned AP-SA02 as a potential first-in-class therapy to demonstrate superiority versus current standard care if confirmed in Phase 3.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Armata Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609140700PR_NEWS_USPR_____LA46593) on September 14, 2026, and is solely responsible for the information contained therein.